Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2/3 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 1Ovarian Neoplasms 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × fosbretabulin × Clear all
NCT02055690 2021-05-17

PAZOFOS

The Christie NHS Foundation Trust

Phase 1/2 Terminated
21 enrolled
Gynecologic

Ovarian Neoplasms

NCT00077103 2010-06-11

Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer

Case Comprehensive Cancer Center

Phase 1/2 Terminated
4 enrolled
EndocrineHead & Neck

Head and Neck Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡